HCW Biologics Inc (HCWB)

Currency in USD
0.407
+0.061(+17.63%)
Closed·
0.380-0.027(-6.63%)
·
Unusual Post-Market activity
HCWB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.3500.407
52 wk Range
0.25017.800
Key Statistics
Prev. Close
0.346
Open
0.35
Day's Range
0.35-0.407
52 wk Range
0.25-17.8
Volume
430.15K
Average Vol. (3m)
8.36M
1-Year Change
-95.1287%
Book Value / Share
1.02
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HCWB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.000
Upside
+391.40%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

HCW Biologics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company’s lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Compare HCWB to Peers and Sector

Metrics to compare
HCWB
Peers
Sector
Relationship
P/E Ratio
−0.1x−5.8x−0.5x
PEG Ratio
0.00−0.070.00
Price / Book
0.8x4.6x2.6x
Price / LTM Sales
43.0x15.9x3.2x
Upside (Analyst Target)
-23.2%47.6%
Fair Value Upside
Unlock−1.3%6.1%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 2.000
(+391.40% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Buy35.00+8,499.51%120.00MaintainMay 29, 2025

Earnings

Latest Release
Mar 31, 2026
EPS / Forecast
-1.02 / -2.43
Revenue / Forecast
27.01K / --
EPS Revisions
Last 90 days

HCWB Income Statement

People Also Watch

1.26
TMDE
-4.89%
4.17
ANNA
-0.71%
1.140
AIXI
+5.56%
0.4040
MGRX
+4.12%

FAQ

What Is the HCW Biologics (HCWB) Stock Price Today?

The HCW Biologics stock price today is 0.407 USD.

What Stock Exchange Does HCW Biologics Trade On?

HCW Biologics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for HCW Biologics?

The stock symbol for HCW Biologics is "HCWB."

What Is the HCW Biologics Market Cap?

As of today, HCW Biologics market cap is 2.330M USD.

What Is HCW Biologics's Earnings Per Share (TTM)?

The HCW Biologics EPS (TTM) is -10.630.

From a Technical Analysis Perspective, Is HCWB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has HCW Biologics Stock Split?

HCW Biologics has split 1 times.

How Many Employees Does HCW Biologics Have?

HCW Biologics has 36 employees.

What is the current trading status of HCW Biologics (HCWB)?

As of Apr 15, 2026, HCW Biologics (HCWB) is trading at a price of 0.407 USD, with a previous close of 0.346 USD. The stock has fluctuated within a day range of 0.350 USD to 0.407 USD, while its 52-week range spans from 0.250 USD to 17.800 USD.

What Is HCW Biologics (HCWB) Price Target According to Analysts?

The average 12-month price target for HCW Biologics is 2.000 USD, with a high estimate of 2 USD and a low estimate of 2 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +391.40% Upside potential.

What Is the HCWB Premarket Price?

HCWB's last pre-market stock price is 0.363 USD. The pre-market share volume is 26,850.000, and the stock has decreased by 0.017, or 4.910%.

What Is the HCWB After Hours Price?

HCWB's last after hours stock price is 0.380 USD, the stock has decreased by -0.027, or -6.630%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.